555 related articles for article (PubMed ID: 24265230)
1. Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
Nguyen HM; Shier KL; Graber CJ
J Antimicrob Chemother; 2014 Apr; 69(4):871-80. PubMed ID: 24265230
[TBL] [Abstract][Full Text] [Related]
2. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
[TBL] [Abstract][Full Text] [Related]
3. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Thomson KS; Moland ES
Antimicrob Agents Chemother; 2001 Dec; 45(12):3548-54. PubMed ID: 11709338
[TBL] [Abstract][Full Text] [Related]
4. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?
Harris PN; Tambyah PA; Paterson DL
Lancet Infect Dis; 2015 Apr; 15(4):475-85. PubMed ID: 25716293
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam.
Peterson LR
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():181-4. PubMed ID: 18154544
[TBL] [Abstract][Full Text] [Related]
6. Management of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: current evidence and future prospects.
Sheu CC; Lin SY; Chang YT; Lee CY; Chen YH; Hsueh PR
Expert Rev Anti Infect Ther; 2018 Mar; 16(3):205-218. PubMed ID: 29402125
[TBL] [Abstract][Full Text] [Related]
7. Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESBL- and AmpC β-lactamase-producing clinical Enterobacteriaceae isolates.
Hombach M; Mouttet B; Bloemberg GV
J Antimicrob Chemother; 2013 Sep; 68(9):2092-8. PubMed ID: 23633681
[TBL] [Abstract][Full Text] [Related]
8. The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae.
Tamma PD; Girdwood SC; Gopaul R; Tekle T; Roberts AA; Harris AD; Cosgrove SE; Carroll KC
Clin Infect Dis; 2013 Sep; 57(6):781-8. PubMed ID: 23759352
[TBL] [Abstract][Full Text] [Related]
9. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI screening parameters for the detection of extended-spectrum β-lactamase production in clinical Enterobacteriaceae isolates.
Polsfuss S; Bloemberg GV; Giger J; Meyer V; Hombach M
J Antimicrob Chemother; 2012 Jan; 67(1):159-66. PubMed ID: 21972269
[TBL] [Abstract][Full Text] [Related]
10. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
[TBL] [Abstract][Full Text] [Related]
11. Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.
D'Angelo RG; Johnson JK; Bork JT; Heil EL
Expert Opin Pharmacother; 2016; 17(7):953-67. PubMed ID: 26891857
[TBL] [Abstract][Full Text] [Related]
12. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
Susić E
Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
[TBL] [Abstract][Full Text] [Related]
13. Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers.
Livermore DM; Hope R; Mushtaq S; Warner M
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():189-93. PubMed ID: 18154546
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a new cefepime-clavulanate ESBL Etest to detect extended-spectrum beta-lactamases in an Enterobacteriaceae strain collection.
Stürenburg E; Sobottka I; Noor D; Laufs R; Mack D
J Antimicrob Chemother; 2004 Jul; 54(1):134-8. PubMed ID: 15150168
[TBL] [Abstract][Full Text] [Related]
15. The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.
Tamma PD; Rodriguez-Bano J
Clin Infect Dis; 2017 Apr; 64(7):972-980. PubMed ID: 28362938
[TBL] [Abstract][Full Text] [Related]
16. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.
Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
Clin Infect Dis; 2013 Feb; 56(4):488-95. PubMed ID: 23090931
[TBL] [Abstract][Full Text] [Related]
17. Extended-spectrum beta-lactamases.
Turner PJ
Clin Infect Dis; 2005 Aug; 41 Suppl 4():S273-5. PubMed ID: 16032564
[TBL] [Abstract][Full Text] [Related]
18. Activity of beta-lactam beta-lactamase inhibitor combinations against extended spectrum Beta-lactamase producing Enterobacteriaceae in urinary isolates.
Afridi FI; Farooqi BJ
J Coll Physicians Surg Pak; 2012 Jun; 22(6):358-62. PubMed ID: 22630093
[TBL] [Abstract][Full Text] [Related]
19. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae.
Livermore DM; Mushtaq S; Ge Y
J Antimicrob Chemother; 2010 Sep; 65(9):1972-4. PubMed ID: 20595207
[TBL] [Abstract][Full Text] [Related]
20. beta-Lactams without a suicide inhibitor.
Giamarellou H
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():194-7. PubMed ID: 18154547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
